| Genetic determinants of response to clopidogrel and cardiovascular events T Simon, C Verstuyft, M Mary-Krause, L Quteineh, E Drouet, N Méneveau, ... New England journal of medicine 360 (4), 363-375, 2009 | 2331 | 2009 |
| Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 925 | 2021 |
| Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity L Bodin, C Verstuyft, DA Tregouet, A Robert, L Dubert, C Funck-Brentano, ... Blood 106 (1), 135-140, 2005 | 508 | 2005 |
| Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients D Anglicheau, P Laurent-Puig, L Becquemont, B Cassinat, P Beaune, ... Journal of the American Society of Nephrology 14 (7), 1889-1896, 2003 | 372 | 2003 |
| Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine, M Resche-Rigon, ... The Lancet Respiratory Medicine 9 (3), 295-304, 2021 | 295 | 2021 |
| Environmental and genetic factors associated with morphine response in the postoperative period L Coulbault, M Beaussier, C Verstuyft, H Weickmans, L Dubert, ... Clinical Pharmacology & Therapeutics 79 (4), 316-324, 2006 | 292 | 2006 |
| Effect of grapefruit juice on digoxin pharmacokinetics in humans L Becquemont, C Verstuyft, R Kerb, U Brinkmann, M Lebot, P Jaillon, ... Clinical Pharmacology & Therapeutics 70 (4), 311-316, 2001 | 252 | 2001 |
| Digoxin pharmacokinetics and MDR1 genetic polymorphisms C Verstuyft, M Schwab, E Schaeffeler, R Kerb, U Brinkmann, P Jaillon, ... European journal of clinical pharmacology 58, 809-812, 2003 | 243 | 2003 |
| Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction … T Simon, PG Steg, M Gilard, D Blanchard, L Bonello, M Hanssen, ... Circulation 123 (5), 474-482, 2011 | 214 | 2011 |
| Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide … HE Meyer zu Schwabedissen, C Verstuyft, HK Kroemer, L Becquemont, ... American Journal of Physiology-Renal Physiology 298 (4), F997-F1005, 2010 | 175 | 2010 |
| Influence of CYP3A5 Genetic Polymorphism on Tacrolimus Daily Dose Requirements and Acute Rejection in Renal Graft Recipients L Quteineh, C Verstuyft, V Furlan, A Durrbach, A Letierce, S Ferlicot, ... Basic & clinical pharmacology & toxicology 103 (6), 546-552, 2008 | 168 | 2008 |
| Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics L Becquemont, A Alfirevic, U Amstutz, H Brauch, E Jacqz-Aigrain, ... Pharmacogenomics 12 (1), 113-124, 2011 | 162 | 2011 |
| The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes ST Zwisler, TP Enggaard, L Noehr‐Jensen, S Mikkelsen, C Verstuyft, ... Fundamental & clinical pharmacology 24 (4), 517-524, 2010 | 128 | 2010 |
| Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations JQ Yang, S Morin, C Verstuyft, LA Fan, Y Zhang, CD Xu, V Barbu, ... Fundamental & clinical pharmacology 17 (3), 373-376, 2003 | 114 | 2003 |
| A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis C Miceli-Richard, E Comets, C Verstuyft, R Tamouza, P Loiseau, ... Annals of the rheumatic diseases 67 (4), 478-484, 2008 | 105 | 2008 |
| Dipyridamole enhances digoxin bioavailability via P‐glycoprotein inhibition C Verstuyft, S Strabach, H El Morabet, R Kerb, U Brinkmann, L Dubert, ... Clinical Pharmacology & Therapeutics 73 (1), 51-60, 2003 | 100 | 2003 |
| PPAR-γ agonists for the treatment of major depression: a review R Colle, D de Larminat, S Rotenberg, F Hozer, P Hardy, C Verstuyft, ... Pharmacopsychiatry 50 (02), 49-55, 2017 | 97 | 2017 |
| Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and … MA Loriot, J Ciccolini, F Thomas, C Barin-Le-Guellec, B Royer, G Milano, ... Bulletin du cancer 105 (4), 397-407, 2018 | 94 | 2018 |
| Effect of paraoxonase‐1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction T Simon, PG Steg, L Becquemont, C Verstuyft, S Kotti, F Schiele, E Ferrari, ... Clinical Pharmacology & Therapeutics 90 (4), 561-567, 2011 | 84 | 2011 |
| Pioglitazone could induce remission in major depression: a meta-analysis R Colle, D de Larminat, S Rotenberg, F Hozer, P Hardy, C Verstuyft, ... Neuropsychiatric Disease and Treatment, 9-16, 2016 | 75 | 2016 |
